SCHEMBL5454329

SCHEMBL5454329

Cc1ccccc1NC(=O)Nc1ccc(N2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
POLB P06746 1/20 0.57
RAB9A P51151 6/20 0.55
NPC1 O15118 5/20 0.55
MAPT P10636 9/20 0.53
DDX3X O00571 4/20 0.53
HTT P42858 2/20 0.52
USP2 O75604 1/20 0.52
TSHR P16473 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
HSD17B10 Q99714 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
LMNA P02545 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
NAMPT P43490 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455899 0.86 MAPT (0.53) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL5459126 0.85 CYP2C19 (0.53) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL5462047 0.85 HTT (0.57) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL5459931 0.85 MEN1 (0.63) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL5463537 0.85 MAPT (0.59) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL5459612 0.85 NPC1 (0.58) KMT2AMEN1POLBRAB9ANPC1
SCHEMBL5465394 0.84 RAB9A (0.75) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL5457972 0.84 NAMPT (0.64) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL5460057 0.84 P2RY1 (0.57) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL5460048 0.82 MAPT (0.51) KMT2AMEN1RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 KMT2A 1350/4885MEN1 1828/4885POLB 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.